At a glance
- Originator Daiichi Sankyo Company
- Class Pyrrolidines; Quinolones; Small molecules
- Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase IV inhibitors; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections; Methicillin-resistant Staphylococcus aureus infections; Tuberculosis
Most Recent Events
- 12 Apr 2006 This compound is still in active development in Japan
- 03 Apr 2006 Daiichi Pharmaceutical has merged with Sankyo to form Daiichi Sankyo Inc
- 02 Feb 2006 Preclinical trials in Tuberculosis in Japan (unspecified route)